Previous studies on somatic mutations in the her2 gene, in human breast cancer patients, revealed several mutations associated with resistance to therapy and/or specific clinicopathological features, reported in National Cancer Institute, International Cancer Genome Consortium and COSMIC databases. Here, ERBB2 is linked to breast cancer.